Source:http://linkedlifedata.com/resource/pubmed/id/20736929
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2010-12-1
|
pubmed:abstractText |
Elimination of specific surface-exposed single tyrosine (Y) residues substantially improves hepatic gene transfer with adeno-associated virus type 2 (AAV2) vectors. Here, combinations of mutations in the seven potentially relevant Y residues were evaluated for further augmentation of transduction efficiency. These mutant capsids packaged viral genomes to similar titers and retained infectivity. A triple-mutant (Y444+500+730F) vector consistently had the highest level of in vivo gene transfer to murine hepatocytes, approximately threefold more efficient than the best single-mutants, and ~30-80-fold higher compared with the wild-type (WT) AAV2 capsids. Improvement of gene transfer was similar for both single-stranded AAV (ssAAV) and self-complementary AAV (scAAV) vectors, indicating that these effects are independent of viral second-strand DNA synthesis. Furthermore, Y730F and triple-mutant vectors provided a long-term therapeutic and tolerogenic expression of human factor IX (hF.IX) in hemophilia B (HB) mice after administration of a vector dose that only results in subtherapeutic and transient expression with WT AAV2 encapsidated vectors. In summary, introduction of multiple tyrosine-mutations into the AAV2 capsid results in vectors that yield at least 30-fold improvement of transgene expression, thereby lowering the required therapeutic dose and potentially vector-related immunogenicity. Such vectors should be attractive for treatment of hemophilia and other genetic diseases.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/F32 HL-096281,
http://linkedlifedata.com/resource/pubmed/grant/HL-076901,
http://linkedlifedata.com/resource/pubmed/grant/P01 DK-058327,
http://linkedlifedata.com/resource/pubmed/grant/P01 HL-078810,
http://linkedlifedata.com/resource/pubmed/grant/R01 AI/HL-51390,
http://linkedlifedata.com/resource/pubmed/grant/R01 AI051390-11,
http://linkedlifedata.com/resource/pubmed/grant/R01 EB-002073,
http://linkedlifedata.com/resource/pubmed/grant/R01 HL-065770
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1525-0024
|
pubmed:author |
pubmed-author:AslanidiGeorge VGV,
pubmed-author:ChenLingL,
pubmed-author:HerzogRoland WRW,
pubmed-author:HoffmanBrad EBE,
pubmed-author:JayandharanGiridhara RGR,
pubmed-author:LiBaozhengB,
pubmed-author:LiMengxinM,
pubmed-author:MaWenqinW,
pubmed-author:MarkusicDavid MDM,
pubmed-author:SrivastavaArunA,
pubmed-author:ZhongLiL,
pubmed-author:ZolotukhinIreneI,
pubmed-author:ZolotukhinSergeiS
|
pubmed:issnType |
Electronic
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2048-56
|
pubmed:dateRevised |
2011-10-4
|
pubmed:meshHeading |
pubmed-meshheading:20736929-Animals,
pubmed-meshheading:20736929-Dependovirus,
pubmed-meshheading:20736929-Gene Therapy,
pubmed-meshheading:20736929-Genetic Vectors,
pubmed-meshheading:20736929-HeLa Cells,
pubmed-meshheading:20736929-Hemophilia B,
pubmed-meshheading:20736929-Hepatocytes,
pubmed-meshheading:20736929-Humans,
pubmed-meshheading:20736929-Mice,
pubmed-meshheading:20736929-Mice, Inbred C57BL,
pubmed-meshheading:20736929-Plasmids,
pubmed-meshheading:20736929-Recombinant Proteins,
pubmed-meshheading:20736929-Transduction, Genetic,
pubmed-meshheading:20736929-Tyrosine
|
pubmed:year |
2010
|
pubmed:articleTitle |
High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.
|
pubmed:affiliation |
Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida 32611, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|